The ATTICA study shows that higher skeletal muscle mass predicts lower cardiovascular disease risk over 10 years. A neuropsychiatric analysis of muscle, heart, and brain health.
Muscle as Medicine: Skeletal Muscle Mass and 10-Year Cardiovascular Risk — What the ATTICA Study Reveals
Posted on December 26, 2025 by the PsychiatryNeurology.net Team
Muscle is rarely discussed in psychiatric circles. When clinicians catalogue risk factors for depression, cognitive decline, or dementia, they reach for the familiar suspects: inflammation, metabolic syndrome, vascular disease, loneliness. But a quiet literature has been accumulating evidence that skeletal muscle mass itself — not just physical activity, not just cardiorespiratory fitness, but the actual quantity and quality of contractile tissue — independently predicts long-term health outcomes, including cardiovascular disease. The ATTICA study, a prospective cohort from Greece, provides some of the most compelling long-term data on this relationship. Its findings, published in the Journal of Epidemiology and Community Health, extend well beyond cardiology: they implicate muscle as a metabolic organ whose preservation matters for the brain as much as for the heart.
This article examines the ATTICA study’s methods, results, and clinical implications. It connects muscle mass to cardiovascular risk through pathways — inflammation, insulin resistance, myokine signaling — that are equally relevant to neuropsychiatric health and longevity.
The ATTICA Study: Design and Key Findings
The ATTICA study is a prospective, population-based investigation launched in 2001–2002 in the Attica region of Greece. It recruited 3,042 adults without pre-existing cardiovascular disease (CVD), aged 18 years and older, and followed them for a decade. The 10-year follow-up, conducted in 2011–2012, captured fatal and non-fatal CVD events in 2,020 participants. For the skeletal muscle analysis, the investigators restricted the sample to 1,019 participants aged 45 years and older (534 men, 485 women) — the age group in whom muscle mass begins to decline measurably and in whom CVD risk becomes clinically actionable.
Skeletal muscle mass (SMM) was estimated indirectly from anthropometric and demographic variables using validated population formulas. Appendicular skeletal muscle mass (ASM) — the sum of lean mass in the arms and legs — was calculated and then standardized by body mass index (BMI) to create a skeletal muscle mass index (SMI). This adjustment is important: it distinguishes between absolute muscle mass and muscle mass relative to body size, isolating the protective component from the confounding effect of overall adiposity. Participants were then grouped into tertiles of SMI.
The primary outcome was 10-year CVD incidence — a composite of myocardial infarction, angina pectoris, other identified ischemia, heart failure, chronic arrhythmia, and stroke, both fatal and non-fatal.
The results were striking. CVD incidence increased significantly across baseline SMI tertiles, with the lowest tertile experiencing the highest event rate (p < 0.001). In fully adjusted models — controlling for age, sex, smoking, physical activity, Mediterranean diet adherence, hypertension, diabetes, hypercholesterolemia, and family history of CVD — each unit increase in SMI was associated with a 94% reduction in 10-year CVD risk (HR 0.06, 95% CI 0.005 to 0.78). When analyzed categorically, participants in the highest SMI tertile had an 81% lower risk for a CVD event compared with those in the lowest tertile (95% CI 0.04 to 0.85). These are large effect sizes, rarely seen outside the most potent pharmacological interventions, and they held after adjustment for physical activity — meaning that muscle mass itself, not just the exercise that builds it, appeared to confer protection.
Muscle as an Endocrine Organ: The Biological Plausibility
Skeletal muscle is not inert scaffolding. It is a metabolically active endocrine organ that secretes hundreds of myokines — signaling molecules that communicate with the liver, adipose tissue, bone, vasculature, and brain. When muscle mass declines, the myokine profile shifts toward a pro-inflammatory state, contributing to the low-grade systemic inflammation that underlies both atherosclerosis and neurodegeneration.
The ATTICA investigators pointed to several mechanisms through which SMM may protect against CVD. First, muscle is the primary site of insulin-mediated glucose disposal. Greater muscle mass improves insulin sensitivity and glucose tolerance, reducing the metabolic substrate for atherogenesis. Second, muscle-derived interleukin-6 (IL-6) is released during contraction and exerts anti-inflammatory effects by inhibiting tumor necrosis factor-alpha and stimulating anti-inflammatory cytokines. In the absence of muscle, this beneficial IL-6 signaling is diminished, and chronic low-grade inflammation — measured by C-reactive protein and other markers — rises.
Third, muscle mass influences resting metabolic rate and energy balance, indirectly regulating adiposity. Adipose tissue, particularly visceral fat, is itself an endocrine organ that secretes adipokines promoting endothelial dysfunction and vascular inflammation. Higher SMM tilts the balance away from adiposity-driven inflammation.
Fourth, myokines such as irisin, cathepsin B, and BDNF may act directly on the vascular endothelium and on the brain. Irisin, released during exercise, promotes browning of white adipose tissue and improves endothelial function. BDNF, a neurotrophin also produced by contracting muscle, enhances hippocampal neuroplasticity and appears to have cardioprotective properties. These overlapping pathways suggest that muscle mass is not only a repository for metabolic health but a nexus connecting cardiovascular and neuropsychiatric resilience.
The Muscle-Brain Axis: Why Neuropsychiatry Should Care
The connection between muscle mass and cardiovascular health matters for psychiatry because the brain and the heart share a vascular tree and a common set of inflammatory risk factors. What predicts myocardial infarction also predicts vascular depression, small vessel brain disease, and cognitive decline. If SMM independently lowers CVD risk, it is reasonable to hypothesize that it also lowers the risk of vascular contributions to late-life depression and dementia.
The myokine BDNF provides a specific mechanistic link. BDNF is diminished in major depressive disorder and in Alzheimer’s disease, and it is upregulated by both aerobic exercise and skeletal muscle contraction. Individuals with sarcopenia — age-related muscle loss — may have a diminished capacity for exercise-induced BDNF release, depriving the hippocampus of a neurotrophic signal essential for neurogenesis and synaptic plasticity. Epidemiological studies have already linked sarcopenia to accelerated cognitive decline and increased risk of depression in older adults, though confounding by physical illness and inactivity remains a concern.
The ATTICA data support a causal chain that runs from muscle mass through metabolic and inflammatory regulation to vascular integrity — and, by extension, to brain health. A patient with low SMM in middle age is not only at elevated risk for a heart attack a decade later; they may also be on a trajectory toward the vascular brain changes that produce cognitive slowing, executive dysfunction, and treatment-resistant depression in older age. The cardiology finding is, in this sense, a neuropsychiatry finding in waiting.
Preserving muscle mass thus becomes a clinical objective that spans disciplines. It is not a niche concern of geriatricians or sports medicine; it is a preventive neuropsychiatric strategy with a decade-long time horizon.
Longevity: The Unifying Frame
If muscle mass protects the heart and the heart protects the brain, then muscle mass is, by logical extension, a variable of longevity. But the relationship is more direct. Sarcopenia is an independent predictor of all-cause mortality in older adults, even after adjusting for multimorbidity and functional status. The ATTICA study adds specificity: it shows that muscle mass measured at baseline predicts incident cardiovascular events — the leading cause of death worldwide — over a full 10-year follow-up. This is a longevity signal, not merely a quality-of-life signal.
From a lifespan perspective, muscle mass peaks in the third decade, plateaus, and then declines at a rate of approximately 1–3% per year after age 50. Resistance training can attenuate this loss, but it cannot fully arrest it. The clinical question is not whether to maintain muscle mass, but at what threshold the risk curve steepens and what interventions — nutritional, hormonal, exercise-based — can shift it. The ATTICA data suggest that even after adjusting for physical activity, SMM mattered, meaning that the sheer quantity of muscle tissue, not just the behavior of exercising, conferred protection. This has implications for individuals who cannot exercise due to disability, pain, or severe depression: strategies to preserve or rebuild muscle mass — through targeted nutrition, supervised resistance training, or in the future, pharmacological myostatin inhibition — may become legitimate components of a longevity-focused treatment plan.
For the neuropsychiatrist, incorporating muscle mass into the clinical picture helps move the conversation from “exercise helps depression” — a generic behavioral prescription — to “muscle mass is a measurable, treatable physiological variable with long-term consequences for your heart and your brain.” It reframes the lifestyle intervention in terms the patient can track: strength, function, body composition, not just mood.
Clinical Implications: Translating the ATTICA Findings
What does a muscle-sensitive clinical practice look like in 2026?
First, the assessment of middle-aged and older patients should, at minimum, include a question about strength and physical function. Grip strength, gait speed, and the chair-rise test are simple, validated proxies for muscle mass and quality that can be performed in an office setting without specialized equipment. They predict CVD, cognitive decline, and mortality with a strength of association that rivals many laboratory biomarkers.
Second, when modifiable cardiovascular risk factors are present — hypertension, dyslipidemia, insulin resistance — the clinical response should extend beyond pharmacotherapy to address muscle mass. This means inquiring about protein intake, resistance exercise, and mobility, and making referrals to physical therapy or exercise physiology where indicated. The ATTICA data suggest that muscle mass is not merely a passive beneficiary of a healthy lifestyle but an active contributor to metabolic and vascular health. Losing muscle in midlife is not a cosmetic concern; it is a cardiovascular risk factor.
Third, for psychiatric patients — particularly those on long-term medications that affect metabolism (antipsychotics, mood stabilizers, certain antidepressants) — monitoring weight alone misses the problem. Weight gain on a psychotropic can mask muscle loss if the patient becomes more sedentary and adipose mass increases while lean mass declines. Body composition analysis, where available, provides a more informative picture. A patient whose BMI is stable but whose muscle mass is declining is not metabolically stable; their cardiovascular and neuropsychiatric risk profile is silently worsening.
Fourth, the longevity framing can be incorporated into patient education. Patients often understand that exercise is “good for the heart” but do not realize that the muscle they build and preserve today directly reduces their risk of a heart attack or stroke years later — and that this same muscle may protect their cognitive function. The ATTICA study provides a specific, evidence-based narrative: a decade-long follow-up of over a thousand adults, showing that those with the most muscle had an 81% lower cardiovascular event rate after controlling for everything else. That is a statistic patients remember.
Limitations and Future Directions
The ATTICA study has limitations that its authors acknowledged. Skeletal muscle mass was not measured directly by DXA or MRI but estimated from population formulas — a method that introduces measurement error, though likely non-differential, which would bias results toward the null. The sample was exclusively Caucasian and Greek, limiting generalizability across ethnic groups, which differ in body composition and cardiometabolic risk profiles. The observational design cannot establish causation, though the temporal ordering — muscle mass measured at baseline, CVD events recorded at 10-year follow-up — strengthens the case for a protective effect.
Future research should test whether interventions that increase or preserve muscle mass — resistance training, protein supplementation, emerging compounds targeting myostatin or activin receptor pathways — reduce cardiovascular event rates in randomized controlled trials. The neuropsychiatric outcomes of such interventions — depression incidence, cognitive trajectory — should be secondary endpoints in those trials. The muscle-brain axis has moved from speculation to a body of indirect evidence; it now awaits direct experimental confirmation.
Frequently Asked Questions
Q: Does muscle mass matter for heart health even if I’m not overweight?
Yes. The ATTICA study adjusted for BMI and physical activity, and the protective association between muscle mass and CVD held. Muscle mass exerts metabolic benefits — improved insulin sensitivity, anti-inflammatory myokine secretion — that are not captured by weight alone.
Q: Can I build enough muscle in middle age to change my risk?
Yes. Resistance training produces measurable gains in muscle mass and strength in previously untrained adults well into their 70s and beyond. The magnitude of the ATTICA association suggests that even modest differences in SMM across tertiles translated into significant risk reductions, so any increase above the lowest tertile is likely beneficial.
Q: Is low muscle mass the same as sarcopenia?
Sarcopenia is the clinical syndrome of age-related loss of muscle mass, strength, and function. The ATTICA study measured estimated muscle mass, not clinical sarcopenia, but the two are closely related. The study’s findings support current clinical guidelines that identify sarcopenia as a modifiable risk factor for cardiovascular disease and mortality.
Q: How does this relate to brain health?
Muscle-derived molecules such as BDNF, irisin, and anti-inflammatory cytokines cross the blood-brain barrier and support neuroplasticity, mood regulation, and cognitive function. Low muscle mass is associated with higher levels of systemic inflammation, which is a risk factor for depression and dementia. Preserving muscle mass may therefore have indirect but meaningful benefits for mental health and cognitive longevity.
Q: What is the best way to measure my muscle mass?
In a clinical setting, DXA scanning is the most accessible, accurate method. Simpler proxies — including grip strength measured with a dynamometer — correlate well with total body muscle mass and with cardiovascular and cognitive outcomes. A conversation with a clinician who understands body composition can clarify the appropriate method.
Also of interest:
